# Latigo Biotherapeutics Raises $150 Million Series B for Non-Opioid Pain Treatment

> financing · REPORTED · 2025-03-01

Latigo Biotherapeutics secured a $150 million Series B round led by Blue Owl Capital to advance its non-opioid pain treatment platform, representing one of the largest early 2025 healthcare venture rounds and signaling strong investor confidence in alternative pain management amid the ongoing opioid crisis. The Thousand Oaks-based company is developing novel analgesic therapies designed to address pain without the addiction risks of opioids.

About Latigo Biotherapeutics: Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid analgesic therapies targeting pain pathways to provide effective pain relief without the addiction and abuse liability associated with opioid medications.

- Company: Latigo Biotherapeutics
- Sector: therapeutics
- Primary source: https://twidh.substack.com/p/healthcare-innovation-attracts-812m

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.